A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
about
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?Insulin degludec as an ultralong-acting basal insulin once a day: a systematic reviewInsulin degludec and insulin aspart: novel insulins for the management of diabetes mellitusLong-term safety and efficacy of insulin degludec in the management of type 2 diabetesFatty acids as therapeutic auxiliaries for oral and parenteral formulationsClinical utility of insulin and insulin analogs.Insulin Degludec Aspart: The First Co-formulation of Insulin AnaloguesMedium-term effects of insulin degludec on patients with type 1 diabetes mellitus.Identifying and meeting the challenges of insulin therapy in type 2 diabetes.Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec.A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review.Impaired glucose metabolism treatment and carcinogenesis.Uncovering undetected hypoglycemic eventsInsulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.Design of non-standard insulin analogs for the treatment of diabetes mellitusInsulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.Future of newer basal insulinA novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial.Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitusInsulin degludec: a significant advancement in ultralong-acting Basal insulin.Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.Treat-to-target trials in diabetes.Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes.Evolution of insulin development: focus on key parameters.IDegAsp: a novel soluble insulin analogs combination.Insulin degludec: overview of a novel ultra long-acting basal insulin.Insulin degludec: a novel basal insulin analogue.Methods to enhance delivery of prandial insulin and basal-prandial insulin.Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action.Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.Insulin analogues in type 1 diabetes mellitus: getting better all the time.A primer on concentrated insulins: what an internist should know.Clinical use of the co-formulation of insulin degludec and insulin aspart.Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.In search of the ideal basal insulin: Does the new-generation ultra-long-acting insulin, degludec, provide the answer?
P2860
Q24624156-AF5EF6D3-E1D3-4224-8071-3713DABC4EA5Q24630395-0D05CC12-DAF5-46BA-ACD5-A92AFFB5D040Q26777076-A75ED043-E1C0-46C7-8EDC-7B88EE333A2CQ26784381-4D484DD4-CC48-49EC-9472-5E28CA981BDEQ26828805-DDC7617E-76D5-4A72-BDB8-67ECD5661225Q30429358-E6DD5A65-D15E-4C6C-B219-F10B4D355743Q33785168-389FCC12-256A-491F-833C-D622A865C52CQ33804815-AEAC7013-293B-4281-8DED-6EBECD774B5AQ33863413-D74B0FD8-4A79-40CF-8999-5A35D651C81AQ34311240-08C3E3C5-BE6E-4F04-94AF-8C14DB0F95FBQ34981168-24D38458-D9C6-41AA-8B6B-A395ED24F182Q35219344-4376C957-5431-45F7-8A66-28E32AE12497Q35870409-21BBABD0-D4F6-48AD-BCF5-905295061F0BQ35922100-894C7C84-4861-45CD-ABB7-50443FD4EC63Q35988978-190B95C0-10C2-463F-A836-02C25430622AQ36103732-61F5F0B5-E09C-43CD-8374-1165808B6389Q36334638-2F0DAF3A-8E2F-41DE-AFB9-7C06A40366CDQ36374363-74DB7B14-29CA-4F5F-AB24-5CD1FF749CABQ36629179-88DA385F-7F2C-429B-A6E9-B8F300DFF391Q36930701-89C0A853-78ED-4FC7-8B14-AE9AD8B227CAQ37421683-99359143-84A4-4564-B1BC-F936FC2E90D3Q37468435-9850A47B-2358-48AF-B93F-F063427B5A7FQ37468486-1AA340B0-0FA5-421B-928D-088A6BE037B7Q37639291-91AFC99D-5A34-4053-8261-8452D4038341Q37703688-88C5295E-F27E-4C02-AFBA-C52BDE2F8EAFQ37972941-A4343DF3-85F6-443D-B7BE-9F1AC20CF15CQ38030454-77616392-22F0-49E8-A36C-7948F0C2CAD8Q38040422-4048997A-623C-4B4E-8085-F4673AF216E8Q38067424-732F509C-D261-4EE2-A4A4-0471884989A8Q38079527-79654AF2-2429-4FBD-B761-455ECC29A530Q38085333-DDCAB278-53FB-49AA-852C-1BD8F4C3DFD6Q38101891-6D49DC20-6887-4EB2-8881-D1D775BED9B7Q38153337-1B6CCF78-FCDD-4100-91C7-76EA72C720CDQ38241834-F85244DA-C3DE-4AC4-9760-B108720D85CBQ38393753-0A6666C1-6B3D-4F1E-9BAC-D84808475CC0Q38692387-4FD0C3E0-2344-4879-B130-A04195F2B6ACQ38754210-3545F393-2B51-499C-9EE4-F37FA3E0E191Q38887939-4818D12C-1F81-4437-99B5-B15E8437641FQ39350860-C676325B-BC07-43C1-998C-218F7BF4E401Q39554211-2A46C1A4-873D-4102-AB9F-533CCA79BA4F
P2860
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A new-generation ultra-long-ac ...... randomized, controlled trial.
@ast
A new-generation ultra-long-ac ...... randomized, controlled trial.
@en
A new-generation ultra-long-ac ...... randomized, controlled trial.
@nl
type
label
A new-generation ultra-long-ac ...... randomized, controlled trial.
@ast
A new-generation ultra-long-ac ...... randomized, controlled trial.
@en
A new-generation ultra-long-ac ...... randomized, controlled trial.
@nl
prefLabel
A new-generation ultra-long-ac ...... randomized, controlled trial.
@ast
A new-generation ultra-long-ac ...... randomized, controlled trial.
@en
A new-generation ultra-long-ac ...... randomized, controlled trial.
@nl
P2093
P2860
P356
P1433
P1476
A new-generation ultra-long-ac ...... randomized, controlled trial.
@en
P2093
Andreas Liebl
Cees J Tack
Didier Gouet
Enrique Romero
Henriette Mersebach
Jaime Davidson
Patrik Dykiel
Robert Cuddihy
Rolf Jorde
P2860
P304
P356
10.2337/DC10-1905
P407
P577
2011-02-01T00:00:00Z